AMN Healthcare Services (NYSE:AMN) Delivers Strong Q2 CY2026 Numbers, Stock Jumps 11.5%

AMN Healthcare Services (NYSE:AMN) reported Q2 CY2026 revenue of $673.2 million, up 2.3% year on year, beating Wall Street expectations. Next-quarter revenue guidance was $647.5 million at the midpoint, about 4.7% above consensus. Non-GAAP EPS was $0.77, above estimates, and the stock rose 11.5% to $34.29. Analysts expect full-year EPS to fall to $0.88.

Original reporting
Published Aug 6, 2026, 11:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMN Healthcare Services (NYSE:AMN) Delivers Strong Q2 CY2026 Numbers, Stock Jumps 11.5% — source image
Decision brief

The 30-second read

$AMNBullishMed
01

Why it matters

The article frames the quarter as a beat on revenue and adjusted EPS plus better-than-expected next-quarter revenue guidance, while also highlighting weak longer-term growth trends and a large expected EPS decline over the next 12 months.

02

Market read

AMN’s earnings and guidance drove an 11.5% stock jump, but the forward EPS outlook described in the article introduces a fundamental overhang.

03

What to watch

Traveler count is down YoY while revenue grew, suggesting pricing rather than volume; traders should scrutinize whether guidance durability depends on temporary staffing rates.

Relevance 8/10Novelty 7/10Timing: post-results, same-day reaction after Q2 CY2026 print

Background

AMN Healthcare Services provides healthcare workforce solutions and reports traveler-on-assignment metrics alongside financial results.

Company-level read

Ticker impact

$AMNBullishMedium confidence
Context

AMN reported Q2 CY2026 revenue of $673.2M (+2.3% YoY) and adjusted EPS of $0.77, beating consensus, and guided next-quarter revenue above expectations.

Expected impact

Bullish bias for the next few sessions, with elevated volatility as traders reconcile beat-and-guide versus expected 12-month EPS contraction.

Evidence & confidence

The article cites a same-day stock jump of 11.5% plus beat on EPS and revenue, but also states sell-side expects full-year EPS to fall 74.7% from $3.48 to $0.88, which can cap follow-through.

Market effects

Healthcare staffing demand and pricing dynamics may look steadier if AMN’s traveler trends and margin expansion persist.

No specific regional impact described beyond US healthcare staffing operations.

Limited global spillover; story is company-specific within US staffing.

Counterpoint

The beat may be partly price-driven and margin may not sustain, especially with the article’s expectation of a steep full-year EPS drop.

Key entities

  • AMN Healthcare Services

    NYSE-listed healthcare staffing firm reporting Q2 CY2026 results and next-quarter revenue guidance.

Related articles

$AMNHighAI 9/10

AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS

AMN Healthcare Services (NYSE: AMN) reported Q2 2026 revenue of $673 million, up 2% year over year, and adjusted EBITDA of $73 million. GAAP net income was $21 million, or $0.53/share, and adjusted EPS was $0.77. The company said results exceeded guidance, citing travel nurse and allied growth, 27% search revenue growth, and acquisitions expanding AI and leadership offerings. Q3 revenue is expected 1-3% higher.

$SHOPMedAI 8/10

Shopify Was Supposed to Be an AI Casualty. Its AI-Referred Traffic Just Tripled.

Shopify (SHOP) reported Q2 results, citing AI-referred traffic to merchants’ storefronts that tripled year over year and orders that began with AI search also tripled. New buyers from AI channels placed orders at nearly twice the rate of other channels. Revenue rose 34% to $3.6B, GMV reached $115.6B, operating income rose 68% to $488M, and free cash flow was $654M.

$GPRKMed

Geopark Q2 Earnings Call Highlights

Geopark (NYSE:GPRK) reported Q2 earnings call updates. It plans $40m to $50m of Vaca Muerta investment in 2H 2026 after $55m in 1H, with 70% to 80% in Q3. Full-year lifting costs are guided at $17 to $19/bbl. Cash rose to $316m, net leverage fell to 1.2x EBITDA, and a $0.023/share quarterly dividend was declared.

$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

$GPNMed

Global Payments Q2 Earnings Call Highlights

Global Payments (NYSE:GPN) reported Q2 results and discussed its Worldpay integration and Genius point-of-sale rollout. Management guided for about 4.5% revenue growth in 2H, margins near 43%, and cited drivers including sales-force ramp and enterprise go-lives. Q2 adjusted net revenue by segment: SMB $1.51B, Enterprise $838M, Platforms $628M. Adjusted free cash flow was $687M; net leverage just below 3.5x.

$CXWMed

Private prisons announce $1.4 billion in revenue as immigration detentions climb

CoreCivic and GEO Group reported combined $1.4 billion in quarterly revenue for April-June as U.S. immigration detention nears record levels. CoreCivic said revenue rose 27% to $684.9 million, including a $1.6 billion DHS facility sale not yet reflected. GEO Group reported $732.1 million revenue, up 15%, with growth in ICE ankle monitoring and related services.